Infinity Pharmaceuticals Inc. (INFI) Sank To A New Low On Phase 2 Study News

Infinity Pharmaceuticals Inc. (INFI) announced Tuesday morning that its Phase 2 study of duvelisib its primary endpoint of overall response rate.

from RTT - Before the Bell http://ift.tt/1Yrqfhv
via IFTTT